Perfluoroctylbromide as a gastrointestinal contrast agent for MR imaging: use with and without glucagon.
The utility of perfluoroctylbromide (PFOB) as a gastrointestinal contrast agent for magnetic resonance (MR) imaging was evaluated with MR examinations performed in 30 subjects (16 healthy volunteers and 14 patients). Transaxial T1-, proton density-, and T2-weighted MR images were acquired in each subject before and after the administration of PFOB. The healthy volunteers each underwent two sets of post-PFOB MR examinations, one before and one after glucagon administration. The degree of bowel marking, clarity of bowel-wall visualization, ability to distinguish bowel from adjacent parenchymal organs, and severity of phase-encoding artifacts were independently analyzed by two reviewers. Oral administration of PFOB significantly (P less than .001) increased the percentage of bowel loops with low signal intensity. Subcutaneous administration of glucagon significantly (P less than .001) increased the clarity of bowel-wall visualization on post-PFOB MR studies. The severity of phase-encoding artifacts did not change substantially after administration of PFOB or glucagon.
Mallinckrodt Institute of Radiology, Washington University Medical Center, St. Louis, MO 63110.
J J
JJ
Brown
J R
JR
Duncan
J P
JP
Heiken
D M
DM
Balfe
A P
AP
Corr
S A
SA
Mirowitz
S S
SS
Eilenberg
J K
JK
Lee
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003287:Contrast Media; D005260:Female; D005466:Fluorocarbons / Q000009:adverse effects; D005934:Glucagon / Q000008:administration & dosage* / Q000494:pharmacology; D006801:Humans; D006842:Hydrocarbons, Brominated; D007089:Image Enhancement; D007422:Intestines / Q000187:drug effects / Q000473:pathology*; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D015588:Observer Variation; D010528:Peristalsis / Q000187:drug effects
D003287:Contrast Media; D005466:Fluorocarbons; D006842:Hydrocarbons, Brominated; D005934:Glucagon; C003072:perflubron